Disparities Exist in Delivering Innovative Cancer Therapies


How can disparities be mitigated when it comes to giving patients the newest and most innovative cancer treatments?

Delivering new and innovative cancer therapies, such as CAR T-cell therapy, come with disparities, explained John Sweetenham, MD, FACP, FRCP, director of clinical affairs and physician in chief at Huntsman Cancer Institute, University of Utah, in Salt Lake City.

These disparities go beyond those that first come to mind, such as race and ethnicity. Patients face barriers in entering clinical trials and receiving the latest standard of care if they live in rural areas.

Three aspects could help fix this problem, said Sweetenham: more education about new advances; more robust funding systems; and a more sophisticated technological platform for clinicians to communicate with patients.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
© 2024 MJH Life Sciences

All rights reserved.